期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
The Polymorphism and Transformation of (3aRS, 4RS, 7RS, 7aSR)-2-(Tricyclo[3.3.1.13,7]decan-1-yl)-4,5,6,7-tetrahydro-4,7-eposyisoindoline-1,3-dione (SU2162)—A Novel Anticancer Compound
1
作者 Yuqing Huang Zaiyou Tan +5 位作者 Lin Luo Hui Yang Chunmei Tong Wenfei Chen Tingyu Huang Ruiling Liu 《Journal of Crystallization Process and Technology》 2014年第1期27-30,共4页
Objective: To determine the transformation between two known crystal forms of the title compound (C18H23NO3, Mr = 301.37). Methods: To recrystallize or heat the crystals and determine the crystal form by testing the m... Objective: To determine the transformation between two known crystal forms of the title compound (C18H23NO3, Mr = 301.37). Methods: To recrystallize or heat the crystals and determine the crystal form by testing the melting points. Results: Both the two known crystal forms of the title compound can be changed by dissolving into different organic solvents such as acetone and ethyl acetate. Crystal form I was not influenced by heating while crystal form II can be transformed to crystal form I through melting method. Conclusion: Organic solvents have significant influences on the two crystal forms of title compound. Crystal form I shows a better thermal stability than crystal form II. 展开更多
关键词 su2162 POLYMORPHISM Crystal Form MELTING METHOD SOLVENT METHOD
下载PDF
Preparation and Characterization of Two Polymorphs of (3aRS,4RS,7RS,7aSR)-2-(Tricyclo[3.3.1.1<sup>3,7</sup>]decan-1-yl)-4,5,6,7-tetrahydro-4,7-eposyisoindoline-1,3-dione (SU2162) with PXRD and DSC
2
作者 Wenfei Chen Zaiyou Tan +7 位作者 Lin Luo Ruisi Yan Hui Yang Chunmei Tong Yuqing Huang Tingyu Huang Yang Yang Ruonan Wang 《Advances in Materials Physics and Chemistry》 2015年第1期16-21,共6页
Objective: To develop the characterization of the polymorphs and the best preparation method of two forms of the title compound (SU2162). After SU2162 was prepared in accordance with the patent process, the crystal fo... Objective: To develop the characterization of the polymorphs and the best preparation method of two forms of the title compound (SU2162). After SU2162 was prepared in accordance with the patent process, the crystal form I was recrystallized by ethyl acetate and the crystal form II was obtained by the recrystal in acetone. And the two crystal forms were characterized with differential scanning calorimetry (DSC) and X-ray powder diffraction (PXRD). The melting point of crystal form I (triclinic) is at 158&deg;C, and the melting point of crystal form II (monoclinic) is at 163&deg;C. The PXRD studies of the two crystalline samples indicate that they have the distinct diffraction patterns. The method herein can be stably prepared for the two crystal forms of the title compound. 展开更多
关键词 su2162 Crystal Form DSC PXRD
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部